相关实验视频

Updated: Jul 16, 2025

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

在鼻腔状细胞癌中用于器官保存的新辅助化疗

Tian Wang¹, Yi Li², Li Wang¹

¹Department of Radiation Oncology, Eye & ENT Hospital, Fudan University, 83 Fenyang Road, Shanghai, 200031, China.

European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery

|September 14, 2023

概括

诱导化疗 (IC) 在晚期鼻腔状细胞癌 (SNSCC) 中显示出显著的响应率. 响应IC的患者经历了改善的生存率和器官保存率,突出了其在治疗中的作用.

科学领域:

在瘤学瘤学.
头部和部癌症研究研究
化疗疗的有效性化疗的有效性

背景情况:

局部发达的鼻腔状细胞癌 (SNSCC) 是一个治疗挑战.
诱导化疗 (IC) 在优化SNSCC治疗结果中的作用需要进一步阐明.

研究的目的:

评估诱导化疗 (IC) 在患有局部发达鼻腔状细胞癌 (SNSCC) 患者的疗效.
确定IC反应对治疗策略,器官保存和长期生存结果的影响.

主要方法:

在2010年至2022年期间接受了IC的130名晚期SNSCC患者的回顾性评估.
对IC的客观反应分析,随后的治疗方式 (化疗/放射治疗+/-手术),器官保存率和生存指标 (OS,PFS,LRFS,DMFS).

主要成果:

在66.9%的患者中观察到部分对IC的反应.
响应IC的患者表现出明显优异的3年整体存活率 (61.2%对37.3%),无进展存活率 (51.3%对33.5%),无局部存活率 (52.1%对35.9%) 和远程无转移存活率 (58.1%对36.1%).
强度回应患者也实现了更高的器官保存率 (90.8%vs74.4%),并从CRT/RT之后的手术中获益最多.

结论:

诱导化疗 (IC) 与晚期SNSCC的显着反应率有关.
对IC的反应是改善存活率和加强器官保存的重要预测因素.
IC反应指导最佳治疗选择,特别有利于CRT/RT,然后对响应者进行手术.

关键词:

化学疗法或放射疗法诱导化疗是一种诱导化疗.器官的保存器官的保存鼻皮状细胞癌的癌症生存结果的结果.

更多相关视频

Role of Diffusion MRI Tractography in Endoscopic Endonasal Skull Base Surgery

Role of Diffusion MRI Tractography in Endoscopic Endonasal Skull Base Surgery

Published on: July 5, 2021

Identification of OTX1 and OTX2 As Two Possible Molecular Markers for Sinonasal Carcinomas and Olfactory Neuroblastomas

Identification of OTX1 and OTX2 As Two Possible Molecular Markers for Sinonasal Carcinomas and Olfactory Neuroblastomas

Published on: February 28, 2019

相关概念视频

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: 5-HT₃ Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...